Myriad offers an array of genetic tests, prognostic tests, and personalized medicine tests to healthcare providers to help them assess a patient's increased cancer risk, disease aggressiveness and optimize efficacy of chemotherapy. Myriad’s testing products can help healthcare providers make medical management decisions to reduce cancer risk and help make sure specific treatments are tailored for each individual patient. We offer leading-edge customer service teams dedicated to the support of our customers through our program called the MyriadPromise.
For more information about our hereditary cancer tests which help healthcare providers assess increased risk for breast, ovarian, colon, uterine, pancreatic and other common cancers, please visit www.myriadpro.com.
For more information about OnDose® testing which evaluates 5-FU exposure for patients undergoing continuous infusion 5-FU chemotherapy, please visit www.ondose.com
For more information about Prolaris® testing, which assesses the prostate cancer aggressiveness in conjunction with other clinical parameters, please visit www.prolaristest.com.